Posted by Shawn. T. on October 22, 2005, at 15:49:40
In reply to Re: NRP104 - D-amphetamine bonded with Lysine?, posted by Larry Hoover on October 19, 2005, at 6:37:21
I didn't just infer that. On New River's website, it is stated that "The binding of the adjuvant renders the active pharmaceutical ingredient essentially inactive until it is broken down into its component parts. We believe that this breakdown only occurs at specifically-targeted sites of enzymatic activity in the body. In the case of our current Carrierwave™ compounds, the site of enzymatic activity is primarily in the gastrointestinal tract. At the target site, enzymes hydrolyze or cleave the adjuvant from the active pharmaceutical ingredient, releasing the active pharmaceutical ingredient into circulation.
While we have not fully established the mechanisms of absorption involved in our Carrierwave™ technology, we believe that the rate of release of the active pharmaceutical ingredient from the CBD is subject to a "saturation effect," which occurs when the CBD is administered in doses greater than that which can be accommodated by the enzymatic processes in the gastrointestinal tract."
I find your claim that NRP104 does not exhibit delayed release in any way to be quite specious. New River has said that "NRP104 demonstrated bioavailability comparable to that of currently-marketed, extended release amphetamine- based products." (http://www.wrhambrecht.com/ind/auctions/openipo/nrph/nrph20040805.pdf)
poster:Shawn. T.
thread:567520
URL: http://www.dr-bob.org/babble/20051017/msgs/570496.html